I 
1. 
BACKGROUND INFORMATION ON THE PROCEDURE 
Submission of the dossier 
The  company  Mallinckrodt  Medical  GmbH  submitted  on  26  February  1997  an  application  for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for  Optison, through the centralised procedure. After agreement by the CPMP on 17 July 1996, this 
medicinal product was referred to Part B of the Annex to Council Regulation No (EC) 2309/93 of 22 
July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Prof. K Strandberg 
Co-Rapporteur:  Dr. H. Pittner 
(replaced by Dr. C. Wirthumer) 
Licensing status  
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 21 March 1997. 
The Rapporteur's first assessment report was circulated to all CPMP Members on 30 May 1997. 
The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 
2 June 1997. 
During the meeting on 22-23 July 1997 the CPMP agreed on the consolidated list of questions 
to be sent to the company. The final consolidated list of questions was sent to the Company on 
23 July 1997 
The  company  submitted  the  responses  to  the  consolidated  list  of  questions  on  6  November 
1997. 
The Rapporteur circulated the joint response assessment report on the company’s responses to 
the list of questions to all CPMP Members on 17 December 1997. 
An updated joint assessment report was circulated to all CPMP members on 23 January 1998. 
The  company  submitted  a  letter  of  undertaking  dated  26  January  1998,  to  provide  further 
information relating to post-opinion followup measures, by the agreed deadlines. In this letter of 
undertaking, the company agreed that only those batches of albumin which have been tested and 
released  by  an  EU  national  control  authority  will  be  used  in  the  preparation  of  the  finished 
product. 
During the meeting on 26-28 January 1998 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Optison on 28 January 1998. 
The  CPMP  opinions  were forwarded, in all  official languages of the  European Union,  to  the European 
Commission, which adopted the corresponding Decisions on 18 May 1998. 
1/1 
EMEA 2004 
 
 
 
 
